Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FUTURE 3 extension study
NL-OMON27501Phase 3Not yet recruiting
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Feb 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of bosentan in pulmonary arterial hypertension (PAH), Plexogenic Pulmonary Arteriopathy, Heritable Pulmonary Arterial Hypertension (HPAH) and 1 more (2 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: No primary endpoint defined. Planned start Feb 2011; status: not yet recruiting.
02
Drugs
bosentan
03
Conditions
pulmonary arterial hypertension (PAH)Plexogenic Pulmonary ArteriopathyHeritable Pulmonary Arterial Hypertension (HPAH)congenital heart disease-associated pulmonary hypertension (CHD-PAH)
Beyond the preview
Go deeper on NL-OMON27501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27501.